Search
Influenza A virus A/Switzerland/9715293/2013 (H3N2) live (attenuated) antigen
go.drugbank.com/drugs/DB11035ApprovedWithdrawnInactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.
Influenza B virus B/Brisbane/60/2008 live (attenuated) antigen
go.drugbank.com/drugs/DB11037ApprovedInvestigationalWithdrawnInactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.
Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated)
go.drugbank.com/drugs/DB11040ApprovedWithdrawnInactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.
Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated)
go.drugbank.com/drugs/DB11041ApprovedWithdrawnInactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.
Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (propiolactone inactivated)
go.drugbank.com/drugs/DB11042ApprovedWithdrawnInactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.
Influenza B virus B/Massachusetts/2/2012 BX-51B antigen (propiolactone inactivated)
go.drugbank.com/drugs/DB11046ApprovedWithdrawnInactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.
Roledumab
go.drugbank.com/drugs/DB16317InvestigationalRoledumab is under investigation in clinical trial NCT02287896 (Pharmacokinetics and Safety of Roledumab in Rhd-negative Pregnant Women Carrying an Rhd-positive Foetus).
Tesnatilimab
go.drugbank.com/drugs/DB16377InvestigationalTesnatilimab is under investigation in clinical trial NCT04655807 (A Study of JNJ-64304500 as Add-on Therapy in Participants With Active Crohn's Disease).
ZEN-3694
go.drugbank.com/drugs/DB22031InvestigationalZEN-3694 is under investigation in clinical trial NCT04840589 (Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid Tumors).
Synonyms: BETi ZEN-3694